New York, NY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bowen Acquisition Corp (NASDAQ:BOWN) ("BOWN"), a special purpose acquisition company, announced the execution of an agreement and plan of merger (the "Merger Agreement") with Shenzhen Qianzhi BioTechnology Co., Ltd ("Qianzhi BioTech"), a biotech company engaged in development, manufacturing and sales of ozonated health and wellness products in China. Pursuant to the Merger Agreement, BOWN's wholly owned subsidiary, Bowen Merger Sub, a Cayman Islands exempted company, will merge (the "Merger" or the "Business Combination") with and into Qianzhi Group Holding (Cayman) Limited, parent of Qianzhi BioTech and an exempted company incorporated with

10-K - Bowen Acquisition Corp (0001973056) (Filer)

8-K - Bowen Acquisition Corp (0001973056) (Filer)

NT 10-K - Bowen Acquisition Corp (0001973056) (Filer)

DEF 14A - Bowen Acquisition Corp (0001973056) (Filer)

425 - Bowen Acquisition Corp (0001973056) (Subject)

8-K - Bowen Acquisition Corp (0001973056) (Filer)

8-K - Bowen Acquisition Corp (0001973056) (Filer)

PRE 14A - Bowen Acquisition Corp (0001973056) (Filer)

SCHEDULE 13G/A - Bowen Acquisition Corp (0001973056) (Subject)

SCHEDULE 13G - Bowen Acquisition Corp (0001973056) (Subject)